Clinical Trials Directory

Trials / Completed

CompletedNCT07093723

Protein S100B Versus Neutrophils/Lymphocytes Ratio in Early Prediction of Brain Injury

Status
Completed
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
28 Weeks – 36 Weeks
Healthy volunteers
Not accepted

Summary

The study aimed to evaluate the role of Protein S100B versus the neutrophil-to-lymphocyte ratio (NLR) as an early predictor biomarker and the value of amplitude-integrated electroencephalography (aEEG) as an early predictor and prognostic method for neonatal brain injury susceptibility and severity.

Detailed description

The most prevalent types of newborn brain injury (NBI) are intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), and hypoxic-ischemic encephalopathy (HIE), which can affect neonates born at any gestational age (GA). Amplitude-integrated EEG (aEEG) is another early predictor and prognostic technique for Neonatal Brain Injury. Electrophysiological brain activity, as measured by aEEG, is a well-established method for giving information on the functional and metabolic status of the brain and the incidence of epileptic seizure episodes. S100B belongs to the S100 family. Because it is soluble in a 100% saturated solution of ammonium sulfate, it was designated "S100." S100 protein is a calcium-binding cytosolic protein with a molecular weight of 21 kDa comprised of 2 monomers, which are found in a variety of cells and are primarily concentrated in the glial cells of the CNS. Due to its molecular weight, peripheral blood will detect only S100B. The neutrophil-to-lymphocyte ratio (NLR) reflects changes in neutrophil and lymphocyte levels, which is an indication of inflammation.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTS100B ProteinSerum level of S100B Protein was measured on the first and third days of seizure activity by ELISA.
DIAGNOSTIC_TESTNeutrophils to Lymphocytes ratioNeutrophils to Lymphocytes ratio was measured on the first and third day of seizure activity obtained by complete blood count.

Timeline

Start date
2023-09-01
Primary completion
2024-03-01
Completion
2024-03-01
First posted
2025-07-30
Last updated
2025-07-30

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07093723. Inclusion in this directory is not an endorsement.